Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2436574
Max Phase: Preclinical
Molecular Formula: C23H23ClF3N3O3
Molecular Weight: 481.90
Molecule Type: Small molecule
Associated Items:
ID: ALA2436574
Max Phase: Preclinical
Molecular Formula: C23H23ClF3N3O3
Molecular Weight: 481.90
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=C(Nc1ccc(OC(F)(F)F)cc1)N1CCC2(CCN(C(=O)c3ccccc3Cl)CC2)C1
Standard InChI: InChI=1S/C23H23ClF3N3O3/c24-19-4-2-1-3-18(19)20(31)29-12-9-22(10-13-29)11-14-30(15-22)21(32)28-16-5-7-17(8-6-16)33-23(25,26)27/h1-8H,9-15H2,(H,28,32)
Standard InChI Key: AUIPYQUAOVXXPQ-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 481.90 | Molecular Weight (Monoisotopic): 481.1380 | AlogP: 5.40 | #Rotatable Bonds: 3 |
Polar Surface Area: 61.88 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 1 |
#RO5 Violations: 1 | HBA (Lipinski): 6 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 13.75 | CX Basic pKa: | CX LogP: 4.83 | CX LogD: 4.83 |
Aromatic Rings: 2 | Heavy Atoms: 33 | QED Weighted: 0.64 | Np Likeness Score: -1.56 |
1. Kato Y, Fuchi N, Saburi H, Nishimura Y, Watanabe A, Yagi M, Nakadera Y, Higashi E, Yamada M, Aoki T.. (2013) Discovery of 2,8-diazaspiro[4.5]decane-based trisubstituted urea derivatives as highly potent soluble epoxide hydrolase inhibitors and orally active drug candidates for treating hypertension., 23 (21): [PMID:24035338] [10.1016/j.bmcl.2013.08.054] |
Source(1):